Pub Date : 2023-09-26DOI: 10.25259/asjo-2022-28-(372)
Sanket Bandyopadhyay, Debasmita Chatterjee, Banhishikha Singh, Krishnendu Paira, Satadal Das
Objectives In this study we explored Bryonia alba as a new anti-cancer agent against liver cancer cells. Material and Methods The Bryonia 6C - an alternative medicine was applied on HepG2 liver cancer cell line to find out its effectiveness indicating morphological and cytokine changes by observing cytopathic effect and RT-PCR study. Results The result showed a possible anti-cancer effect of Bryonia 6C with degenerative changes on the cancer cells. A cytokine imbalance was also noticed within 24 hours detrimental to the malignant environment of these cells. Conclusion The alternative medicine Bryonia 6C is an effective anticancer agent against liver cancer cells.
{"title":"Action of ultra-diluted ethanol extract of <i>Bryonia alba</i> on HepG2 liver cancer cells","authors":"Sanket Bandyopadhyay, Debasmita Chatterjee, Banhishikha Singh, Krishnendu Paira, Satadal Das","doi":"10.25259/asjo-2022-28-(372)","DOIUrl":"https://doi.org/10.25259/asjo-2022-28-(372)","url":null,"abstract":"Objectives In this study we explored Bryonia alba as a new anti-cancer agent against liver cancer cells. Material and Methods The Bryonia 6C - an alternative medicine was applied on HepG2 liver cancer cell line to find out its effectiveness indicating morphological and cytokine changes by observing cytopathic effect and RT-PCR study. Results The result showed a possible anti-cancer effect of Bryonia 6C with degenerative changes on the cancer cells. A cytokine imbalance was also noticed within 24 hours detrimental to the malignant environment of these cells. Conclusion The alternative medicine Bryonia 6C is an effective anticancer agent against liver cancer cells.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134958747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-16DOI: 10.25259/asjo-2022-27-(371)
Bella Yunita, Rahmat Cahyanur
Hypercalcemia is a complication that is often found in patients with malignancy, both blood malignancy and solid tumor malignancy, with a prevalence that can reach 30%. Hypercalcemia caused by malignant conditions is usually characterized by severe clinical manifestations, severe degree, and rapid onset. Hypercalcemia is also one of the markers of poor prognosis in patients with malignancy, often a sign that a malignant condition is in the late stages or is refractory to the treatment given. Management of hypercalcemia in malignancy is based on the underlying pathophysiology. The main pathophysiology is due to humoral hypercalcemia, local osteolytic metastases, increased extrarenal calcitriol, and primary or ectopic PTH secretion. Based on this condition, an understanding of the pathophysiology, clinical manifestations, diagnostic approach, and management of hypercalcemia in malignancy needs to be studied further.
{"title":"Pathophysiology and management of hypercalcemia in malignancy","authors":"Bella Yunita, Rahmat Cahyanur","doi":"10.25259/asjo-2022-27-(371)","DOIUrl":"https://doi.org/10.25259/asjo-2022-27-(371)","url":null,"abstract":"Hypercalcemia is a complication that is often found in patients with malignancy, both blood malignancy and solid tumor malignancy, with a prevalence that can reach 30%. Hypercalcemia caused by malignant conditions is usually characterized by severe clinical manifestations, severe degree, and rapid onset. Hypercalcemia is also one of the markers of poor prognosis in patients with malignancy, often a sign that a malignant condition is in the late stages or is refractory to the treatment given. Management of hypercalcemia in malignancy is based on the underlying pathophysiology. The main pathophysiology is due to humoral hypercalcemia, local osteolytic metastases, increased extrarenal calcitriol, and primary or ectopic PTH secretion. Based on this condition, an understanding of the pathophysiology, clinical manifestations, diagnostic approach, and management of hypercalcemia in malignancy needs to be studied further.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"354 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135306435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-09DOI: 10.25259/asjo-2021-66-(298)
Jeremiah R. Vallente, Carlo Francisco N. Cortez, Ma. Angelina L. Mirasol
Objectives The Filipino population is largely underrepresented in the currently available literature on multiple myeloma (MM). Herein, we aimed to determine the clinical profile, treatment, and outcomes of adult Filipinos with MM. Material and Methods The records of 74 patients with MM seen at our institution from 2016 to 2019 were retrospectively reviewed. Results The median age at diagnosis was 54 years, with the majority lumped in the 40–65 years age group. At diagnosis, anemia (hemoglobin <100 g/L) was present in 36 (64.3%) patients, but hypercalcemia (calcium ≥2.75 mmol/L) and azotemia (creatinine ≥177 umol/L) were seen in only 9 (20.0%) and 18 (34.0%) patients, respectively. Novel drugs (bortezomib, thalidomide, and lenalidomide) were used in 54 (84.4%) patients for frontline treatment. The overall response rate was 70.0% and the median overall survival (OS) was 60 months. On univariate analysis, only hemoglobin and the serum albumin levels affected survival. Conclusion Aside from the trend of a younger age at diagnosis, there are no unique clinical characteristics of MM seen in Filipinos. The longer OS may reflect the availability of newer drugs in the recent decade, but larger studies are needed to investigate the prognostic significance of several clinical and treatment parameters.
{"title":"Clinical profiles and survival outcomes of adult patients with multiple myeloma at a tertiary hospital in the Philippines","authors":"Jeremiah R. Vallente, Carlo Francisco N. Cortez, Ma. Angelina L. Mirasol","doi":"10.25259/asjo-2021-66-(298)","DOIUrl":"https://doi.org/10.25259/asjo-2021-66-(298)","url":null,"abstract":"Objectives The Filipino population is largely underrepresented in the currently available literature on multiple myeloma (MM). Herein, we aimed to determine the clinical profile, treatment, and outcomes of adult Filipinos with MM. Material and Methods The records of 74 patients with MM seen at our institution from 2016 to 2019 were retrospectively reviewed. Results The median age at diagnosis was 54 years, with the majority lumped in the 40–65 years age group. At diagnosis, anemia (hemoglobin <100 g/L) was present in 36 (64.3%) patients, but hypercalcemia (calcium ≥2.75 mmol/L) and azotemia (creatinine ≥177 umol/L) were seen in only 9 (20.0%) and 18 (34.0%) patients, respectively. Novel drugs (bortezomib, thalidomide, and lenalidomide) were used in 54 (84.4%) patients for frontline treatment. The overall response rate was 70.0% and the median overall survival (OS) was 60 months. On univariate analysis, only hemoglobin and the serum albumin levels affected survival. Conclusion Aside from the trend of a younger age at diagnosis, there are no unique clinical characteristics of MM seen in Filipinos. The longer OS may reflect the availability of newer drugs in the recent decade, but larger studies are needed to investigate the prognostic significance of several clinical and treatment parameters.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136194035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-03DOI: 10.25259/asjo-2022-36-(391)
Doaa Naeem, Hanan Kamal Abdelaziz, Nadia Ahmed Barghash, M. Soliman, Hazem Farag Mannaa
Breast cancer (BC) is a major global health issue as it is the most common malignancy in women. Despite, the role of neoadjuvant chemotherapy (NAC) in early BC has been established, there is a non-small proportion of patients who might develop chemoresistance. Several studies have investigated the relationship between microRNA-210 (miRNA-210) and neoadjuvant chemoresistance in BC with controversial results. Thus, this study aimed to evaluate the role of miRNA-210 as a predictor for chemoresistance in BC receiving NAC. The study enrolled 15 chemo-sensitive and 15 chemo-resistant patients with BC receiving NAC. In addition, 10 newly-diagnosed BC patients before treatment and 10 healthy women were recruited as controls. Serum samples from all patients and controls were withdrawn and measurements of miRNA-210 levels using quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) were done and compared. The median value of miRNA-210 level was 1.53, 0.27, 0.52, and 1.35 in chemo-sensitive, chemo-resistant, newly-diagnosed, and control groups, respectively. A statistically significant difference (Chi square = 9.801, p = 0.020, df = 3) was found in the mean serum miRNA-210 among the four different groups. Using logistic regression model, low serum miRNA-210 expression level was found to be a predictive factor of chemo-resistance with p = 0.038 (OR of 0.103, 95% CI = 0.012 –0.886). Using the receiver operating characteristic curve, it was found that the area under the curve (AUC) was 0.747 (95% CI = 0.550 –0.943). Serum miRNA-210 could be an effective predictive biomarker for chemoresistance in BC patients receiving NAC.
乳腺癌(BC)是一个主要的全球健康问题，因为它是妇女中最常见的恶性肿瘤。尽管新辅助化疗(NAC)在早期BC中的作用已经确立，但仍有不小比例的患者可能出现化疗耐药。一些研究调查了microRNA-210 (miRNA-210)与BC新辅助化疗耐药的关系，但结果有争议。因此，本研究旨在评估miRNA-210作为接受NAC的BC患者化疗耐药的预测因子的作用。该研究招募了15名化疗敏感和15名化疗耐药的BC患者接受NAC。此外，还招募了10名治疗前新诊断的BC患者和10名健康女性作为对照。提取所有患者和对照组的血清样本，使用定量实时逆转录-聚合酶链反应(qRT-PCR)测量miRNA-210水平并进行比较。化疗敏感组、化疗耐药组、新诊断组和对照组的miRNA-210水平中位数分别为1.53、0.27、0.52和1.35。四组患者血清miRNA-210均值差异有统计学意义(χ 2 = 9.801, p = 0.020, df = 3)。采用logistic回归模型，发现血清miRNA-210低表达水平是化疗耐药的预测因素，p = 0.038 (OR = 0.103, 95% CI = 0.012 ~ 0.886)。利用受试者工作特征曲线，发现曲线下面积(AUC)为0.747 (95% CI = 0.550 -0.943)。血清miRNA-210可能是接受NAC的BC患者化疗耐药的有效预测生物标志物。
{"title":"Serum microRNA-210 as a predictor of neoadjuvant chemotherapy resistance in breast cancer","authors":"Doaa Naeem, Hanan Kamal Abdelaziz, Nadia Ahmed Barghash, M. Soliman, Hazem Farag Mannaa","doi":"10.25259/asjo-2022-36-(391)","DOIUrl":"https://doi.org/10.25259/asjo-2022-36-(391)","url":null,"abstract":"\u0000\u0000Breast cancer (BC) is a major global health issue as it is the most common malignancy in women. Despite, the role of neoadjuvant chemotherapy (NAC) in early BC has been established, there is a non-small proportion of patients who might develop chemoresistance. Several studies have investigated the relationship between microRNA-210 (miRNA-210) and neoadjuvant chemoresistance in BC with controversial results. Thus, this study aimed to evaluate the role of miRNA-210 as a predictor for chemoresistance in BC receiving NAC.\u0000\u0000\u0000\u0000The study enrolled 15 chemo-sensitive and 15 chemo-resistant patients with BC receiving NAC. In addition, 10 newly-diagnosed BC patients before treatment and 10 healthy women were recruited as controls. Serum samples from all patients and controls were withdrawn and measurements of miRNA-210 levels using quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) were done and compared.\u0000\u0000\u0000\u0000The median value of miRNA-210 level was 1.53, 0.27, 0.52, and 1.35 in chemo-sensitive, chemo-resistant, newly-diagnosed, and control groups, respectively. A statistically significant difference (Chi square = 9.801, p = 0.020, df = 3) was found in the mean serum miRNA-210 among the four different groups. Using logistic regression model, low serum miRNA-210 expression level was found to be a predictive factor of chemo-resistance with p = 0.038 (OR of 0.103, 95% CI = 0.012 –0.886). Using the receiver operating characteristic curve, it was found that the area under the curve (AUC) was 0.747 (95% CI = 0.550 –0.943). \u0000\u0000\u0000\u0000Serum miRNA-210 could be an effective predictive biomarker for chemoresistance in BC patients receiving NAC.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47982875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-18DOI: 10.25259/asjo-2022-40-(395)
S. Shanmugam, S. Susikar, Arun Victor Jebasingh
The extent of neck dissection over the years has evolved from a radical neck dissection to a super-selective neck dissection with an attempt to achieve a balance between oncological safety and acceptable morbidity. There is an ongoing debate concerning dissection of level IIB in both node negative and positive patients, primarily due to the low incidence of metastasis in this region and possible spinal accessory nerve injury. In this study, we intended to find the rate of metastasis to level IIB nodes in patients who were treated with neck dissection for oral cancers. Patients with squamous cell carcinoma of the oral cavity who underwent neck dissection were analyzed. Patients with clinically node negative (cN0) disease underwent selective neck dissection (SND), whereas patients with clinically node positive (cN+) disease underwent modified radical neck dissection (MRND). Out of the total 34 patients, 12 patients underwent MRND and 22 patients underwent SND. In the MRND group, three patients (25%) had positive level IIB nodes. The median number of IIB nodes removed was two and the median number of positive IIB nodes was one. In the SND group, the median number of IIB nodes removed was three and none of the patients had positive level IIB node. In oral cancer with cN+, routine dissection of level IIB nodes has both therapeutic and prognostic values. Whereas, in patients with cN0, routine dissection of level IIB nodes can be omitted. Further large volume studies are needed on cN0 disease.
{"title":"Assessment of level IIB lymph nodes in oral cancer - Should we spare or care?","authors":"S. Shanmugam, S. Susikar, Arun Victor Jebasingh","doi":"10.25259/asjo-2022-40-(395)","DOIUrl":"https://doi.org/10.25259/asjo-2022-40-(395)","url":null,"abstract":"The extent of neck dissection over the years has evolved from a radical neck dissection to a super-selective neck dissection with an attempt to achieve a balance between oncological safety and acceptable morbidity. There is an ongoing debate concerning dissection of level IIB in both node negative and positive patients, primarily due to the low incidence of metastasis in this region and possible spinal accessory nerve injury. In this study, we intended to find the rate of metastasis to level IIB nodes in patients who were treated with neck dissection for oral cancers.\u0000\u0000\u0000\u0000Patients with squamous cell carcinoma of the oral cavity who underwent neck dissection were analyzed. Patients with clinically node negative (cN0) disease underwent selective neck dissection (SND), whereas patients with clinically node positive (cN+) disease underwent modified radical neck dissection (MRND).\u0000\u0000\u0000\u0000Out of the total 34 patients, 12 patients underwent MRND and 22 patients underwent SND. In the MRND group, three patients (25%) had positive level IIB nodes. The median number of IIB nodes removed was two and the median number of positive IIB nodes was one. In the SND group, the median number of IIB nodes removed was three and none of the patients had positive level IIB node.\u0000\u0000\u0000\u0000In oral cancer with cN+, routine dissection of level IIB nodes has both therapeutic and prognostic values. Whereas, in patients with cN0, routine dissection of level IIB nodes can be omitted. Further large volume studies are needed on cN0 disease.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41696325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-18DOI: 10.25259/asjo-2022-32-(382)
Mohsina Hussain, A. Adhav, Sirshendu Roy, Yasam Venkata Ramesh, R. Nagarkar
Metaplastic carcinomas of the breast are unusual conditions and account for 0.25% to 1% of annual breast malignancies. Among these, primary metaplastic squamous cell carcinoma (SCC) of the breast is an extremely rare entity occurring in less than 0.1% of all breast carcinomas. Management protocol and survival outcome for metaplastic breast carcinoma is relatively unknown because of the rarity of the disease, but studies suggest that removal of the tumor and adjuvant radiotherapy has the greatest impact. In this paper, we report the occurrence of this rare lesion in a 71-year-old lady who was treated and is recovering uneventfully. Early diagnosis and radical upfront surgery may warrant a good prognosis, as demonstrated in this case report.
{"title":"Metaplastic squamous cell carcinoma of the breast – A rare case report","authors":"Mohsina Hussain, A. Adhav, Sirshendu Roy, Yasam Venkata Ramesh, R. Nagarkar","doi":"10.25259/asjo-2022-32-(382)","DOIUrl":"https://doi.org/10.25259/asjo-2022-32-(382)","url":null,"abstract":"\u0000Metaplastic carcinomas of the breast are unusual conditions and account for 0.25% to 1% of annual breast malignancies. Among these, primary metaplastic squamous cell carcinoma (SCC) of the breast is an extremely rare entity occurring in less than 0.1% of all breast carcinomas. Management protocol and survival outcome for metaplastic breast carcinoma is relatively unknown because of the rarity of the disease, but studies suggest that removal of the tumor and adjuvant radiotherapy has the greatest impact. In this paper, we report the occurrence of this rare lesion in a 71-year-old lady who was treated and is recovering uneventfully. Early diagnosis and radical upfront surgery may warrant a good prognosis, as demonstrated in this case report.","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46638587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-17DOI: 10.25259/asjo-2022-52-(413)
Bhushan Sanjay Bhalgat
Neck dissection is now a part and parcel in management of oral malignancies. Like all other surgical procedures, it has a few morbidities, which include iatrogenic trauma to the spinal accessory nerve leading to atrophy of ipsilateral trapezius and sternocleidomastoid muscle. A few identification markers for the nerve have been described in the literature. The markers or structures described previously are not so accurate and give only an approximate idea of where the nerve could be. We have discovered a simple and easily reproducible marker and a sign which helps us identify the nerve each and every time without fail. The junction of posterior belly of digastric nerve, internal jugular vein, and spinal accessory nerve is the point where the proximal end of the nerve is found, and the structures together form an “upward pointing arrow” which helps identify the nerve precisely during neck dissection.
{"title":"Novel method of identifying spinal accessory nerve during modified radical neck dissection in level 2: “SMS Hospital point” and “Upward Pointing Arrow” sign","authors":"Bhushan Sanjay Bhalgat","doi":"10.25259/asjo-2022-52-(413)","DOIUrl":"https://doi.org/10.25259/asjo-2022-52-(413)","url":null,"abstract":"\u0000\u0000Neck dissection is now a part and parcel in management of oral malignancies. Like all other surgical procedures, it has a few morbidities, which include iatrogenic trauma to the spinal accessory nerve leading to atrophy of ipsilateral trapezius and sternocleidomastoid muscle. A few identification markers for the nerve have been described in the literature. The markers or structures described previously are not so accurate and give only an approximate idea of where the nerve could be. We have discovered a simple and easily reproducible marker and a sign which helps us identify the nerve each and every time without fail. The junction of posterior belly of digastric nerve, internal jugular vein, and spinal accessory nerve is the point where the proximal end of the nerve is found, and the structures together form an “upward pointing arrow” which helps identify the nerve precisely during neck dissection.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46937353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-17DOI: 10.25259/asjo-2022-49-(407)
Souhail El Alami, A. Laraichi, M. Abakka, Naoufal El Ghoul, Soukaina El Aouni, A. Bennis, O. Zaddoug, A. Zine, M. Benchakroun, M. Tanane, S. Bouabid
This study investigates the synchronous traits of a rare lung cancer subtype, specifically Large Cell Neuroendocrine Carcinoma (LCNEC), discovered through bone metastases. Bone metastases are a common occurrence in lung cancer, significantly impacting the quality of life and survival of patients. Synchronous bone metastasis (SBM), defined as bone metastases diagnosed within three months of lung cancer diagnosis, and metachronous bone metastasis (MBM), diagnosed more than three months after lung cancer diagnosis, exhibit distinct clinicopathological characteristics, therapeutic sensitivities, and prognostic outcomes. This article presents a visual case discussion of a 64-year-old male patient who experienced a pathological fracture of the proximal femur, leading to the incidental discovery of LCNEC through bone biopsy. Further imaging and diagnostic tests confirmed the presence of a primary lung tumor and bone metastases. The treatment approach for LCNEC remains challenging due to limited data and varying outcomes reported in the literature, however our patient received cisplatin with etoposide chemotherapy following fracture management. The findings emphasize the importance of recognizing rare lung cancer subtypes, such as LCNEC, through bone metastases and tailoring individualized treatment plans.
{"title":"Rare lung cancer subtype discovery by bone metastases: Synchronous traits","authors":"Souhail El Alami, A. Laraichi, M. Abakka, Naoufal El Ghoul, Soukaina El Aouni, A. Bennis, O. Zaddoug, A. Zine, M. Benchakroun, M. Tanane, S. Bouabid","doi":"10.25259/asjo-2022-49-(407)","DOIUrl":"https://doi.org/10.25259/asjo-2022-49-(407)","url":null,"abstract":"\u0000\u0000This study investigates the synchronous traits of a rare lung cancer subtype, specifically Large Cell Neuroendocrine Carcinoma (LCNEC), discovered through bone metastases. Bone metastases are a common occurrence in lung cancer, significantly impacting the quality of life and survival of patients. Synchronous bone metastasis (SBM), defined as bone metastases diagnosed within three months of lung cancer diagnosis, and metachronous bone metastasis (MBM), diagnosed more than three months after lung cancer diagnosis, exhibit distinct clinicopathological characteristics, therapeutic sensitivities, and prognostic outcomes. This article presents a visual case discussion of a 64-year-old male patient who experienced a pathological fracture of the proximal femur, leading to the incidental discovery of LCNEC through bone biopsy. Further imaging and diagnostic tests confirmed the presence of a primary lung tumor and bone metastases. The treatment approach for LCNEC remains challenging due to limited data and varying outcomes reported in the literature, however our patient received cisplatin with etoposide chemotherapy following fracture management. The findings emphasize the importance of recognizing rare lung cancer subtypes, such as LCNEC, through bone metastases and tailoring individualized treatment plans.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47419444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Bacorro, Stellar Marie Cabrera, M. Bojador, M. Dumago, K. Baldivia, T. S. Sy Ortin
The HYACINCT trial will investigate the role of dose-adapted hypofractionated pelvic radiotherapy in patients with locally advanced cervical cancer who are ineligible for cisplatin. This dummy run evaluated the feasibility of the protocol treatment planning objectives using intensity-modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT). The HYACINCT protocol defines a set of guidelines for image acquisition, target and organ delineation, and treatment planning objectives. Fifteen dummy cases were prepared, five each for three levels of dose requirements: 40 Gy without boost, and with boost to 45 Gy and to 48 Gy. IMRT and VMAT plans were prepared for each case, evaluated and assigned penalty and compliance scores according to planning objectives, and subjected to quality control. IMRT and VMAT plans were compared in terms of treatment plan quality (target coverage, penalty, and compliance scores), and treatment delivery. Tumor extent (T-stage, T-score), nodal status, and PTV volumes (in cc) were examined as potential determinants of penalty and compliance scores. IMRT was able to meet the planning objectives for all but one case; and VMAT, for all cases. All plans passed the quality control check. IMRT and VMAT were equivalent in terms of target coverage and penalty and compliance scores, but the latter was associated with better treatment delivery. T-score was a determinant for the penalty score. The HYACINCT radiotherapy protocol is feasible with either IMRT or VMAT. VMAT may be beneficial in more extensive cases, as measured by the T-score. NCT05210270
{"title":"Feasibility of hypofractionated pelvic radiotherapy with parametrial and nodal simultaneous integrated boost for locally advanced cervical cancers: dummy run for the HYACINCT trial","authors":"W. Bacorro, Stellar Marie Cabrera, M. Bojador, M. Dumago, K. Baldivia, T. S. Sy Ortin","doi":"10.25259/asjo_2_2023","DOIUrl":"https://doi.org/10.25259/asjo_2_2023","url":null,"abstract":"\u0000\u0000The HYACINCT trial will investigate the role of dose-adapted hypofractionated pelvic radiotherapy in patients with locally advanced cervical cancer who are ineligible for cisplatin. This dummy run evaluated the feasibility of the protocol treatment planning objectives using intensity-modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT).\u0000\u0000\u0000\u0000The HYACINCT protocol defines a set of guidelines for image acquisition, target and organ delineation, and treatment planning objectives. Fifteen dummy cases were prepared, five each for three levels of dose requirements: 40 Gy without boost, and with boost to 45 Gy and to 48 Gy. IMRT and VMAT plans were prepared for each case, evaluated and assigned penalty and compliance scores according to planning objectives, and subjected to quality control. IMRT and VMAT plans were compared in terms of treatment plan quality (target coverage, penalty, and compliance scores), and treatment delivery. Tumor extent (T-stage, T-score), nodal status, and PTV volumes (in cc) were examined as potential determinants of penalty and compliance scores.\u0000\u0000\u0000\u0000IMRT was able to meet the planning objectives for all but one case; and VMAT, for all cases. All plans passed the quality control check. IMRT and VMAT were equivalent in terms of target coverage and penalty and compliance scores, but the latter was associated with better treatment delivery. T-score was a determinant for the penalty score.\u0000\u0000\u0000\u0000The HYACINCT radiotherapy protocol is feasible with either IMRT or VMAT. VMAT may be beneficial in more extensive cases, as measured by the T-score.\u0000\u0000\u0000\u0000NCT05210270\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49535045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.25259/asjo-2022-65-(429)
T. Tali, Fiza Amin, ShahidRashid Sofi, M. Sofi, N. Dar
To study the epidemiology and treatment outcome of glioblastoma multiforme in a tertiary care hospital. This was a retrospective study performed in the Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, India, in which clinical and epidemiological details of the 80 cases diagnosed with glioblastoma multiforme from January 2016 to December 2020 were analyzed. The majority of the patients in our study were males, compared to females (n = 57, 23: 71%, 29%). Neurodeficiency and headache were the most common presenting symptoms. All patients were subjected to surgery followed by chemoradiation, and the overall median survival was 13 months. Multimodality therapy, including safe, optimal surgical resection combined with adjuvant radiotherapy or concurrent chemoradiation and sequential chemotherapy, is recommended for all patients with this fatal neoplasm.
{"title":"Epidemiology and outcome of glioblastoma multiforme: A tertiary care experience","authors":"T. Tali, Fiza Amin, ShahidRashid Sofi, M. Sofi, N. Dar","doi":"10.25259/asjo-2022-65-(429)","DOIUrl":"https://doi.org/10.25259/asjo-2022-65-(429)","url":null,"abstract":"\u0000\u0000To study the epidemiology and treatment outcome of glioblastoma multiforme in a tertiary care hospital.\u0000\u0000\u0000\u0000This was a retrospective study performed in the Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, India, in which clinical and epidemiological details of the 80 cases diagnosed with glioblastoma multiforme from January 2016 to December 2020 were analyzed.\u0000\u0000\u0000\u0000The majority of the patients in our study were males, compared to females (n = 57, 23: 71%, 29%). Neurodeficiency and headache were the most common presenting symptoms. All patients were subjected to surgery followed by chemoradiation, and the overall median survival was 13 months.\u0000\u0000\u0000\u0000Multimodality therapy, including safe, optimal surgical resection combined with adjuvant radiotherapy or concurrent chemoradiation and sequential chemotherapy, is recommended for all patients with this fatal neoplasm.\u0000","PeriodicalId":31357,"journal":{"name":"Asian Journal of Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47025883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：